NeuroOne Medical Technologies Corp.

MobiHealthNews’ Emerging Technologies Series spotlights organizations developing, scaling and investing in innovative healthcare technologies. What follows is Part 2 of a seven-part series: Dave Rosa, president and CEO of NeuroOne, sat down with MobiHealthNews to discuss how the company's electrode technology can help treat neurological conditions like epilepsy by recording brain activity, stimulating tissue and, in some cases, ablating tissue to reduce or eliminate seizures. MobiHealthNews: Tell me a bit about NeuroOne. Dave Rosa: NeuroOne is a company that's been around since about 2017. We're a public company that trades on Nasdaq, and what we do is we design and commercialize thin-film electrode technology that's used for neurologic conditions that you've probably heard of, like epilepsy and Parkinson's disease. I call it the brain-pain and drug-delivery company. So, you've got these three different pillars with this unique electro technology that really deal with conditions in the brain, treating pain throughout the body, and then, also the ability, using the same platform, to deliver drugs, like really gene therapies and cell-based therapies for neurological conditions as well. Some of the devices are film, but some of them also look like thin wires. Both technologies can really be placed anywhere in the body. It just depends on the application. MobiHealthNews: So it's not even necessarily a brain implant. Rosa: Not yet. It will be. So that's one of the things that we're working on is to be able to commercialize a device that would be part of a permanent implant, but to kind of distinguish between what we're doing and companies like Neuralink. Most people have heard about Elon Musk's brain company [Neuralink]; what they're doing is a complete system, and they're really targeting things like paralysis. So, they want to be able, at some point, to get someone who is in a wheelchair, that's a quadriplegic, and get them to a point where they're able to get up and walk around. Really, the aspect that we're focused on is the electrode itself, not the hardware, but the film or wire-like technology that communicates with the computer. What we've been able to do is get it to perform multiple functions, like its ability to record what's going on in the brain, the ability to stimulate that brain tissue with the same device, or actually burn the tissue to eliminate things like seizures. While all these devices communicate with the brain. It's not the same as what Neuralink is doing, which is really intended to go after kind of the worst of the worst clinical situations. MobiHealthNews: How does it actually work? Rosa: So, it literally is a material that has metal embedded in it. So, there are different points of contact on the device, metal material, and when that is connected to a machine – think of an EKG because it's probably the easiest example. They put electrodes on your chest to measure what's happening, the electrical activity in your heart. We're doing the same thing, except it's in the brain. And when it's connected to a machine that actually takes that information and puts it into a waveform, it's operating the same way. The only difference is, in addition to that diagnostic piece, we can also actually perform a therapeutic function, either by stimulating that tissue or, when connected to a different piece of equipment, burning that tissue to prevent seizures or other problems from occurring. MobiHealthNews: How many patients have been implanted with the devices? Rosa: We're a public company, and I have to be careful about what we release publicly that hasn't been released already. We haven't given any numbers out. I mean, we've had the technology out now for a little over a year. So, there's a fair amount of patients that have been treated, and every day, you know, we're doing additional cases through our distribution partner, which happens to be Zimmer Biomet, which is a very large, well-known orthopedics company. MobiHealthNews: How effective have the implants shown to be? Rosa: Very effective. In fact, one of our patients was highlighted on "Good Morning America." It was really the story of a young teenage girl who got to the point where she could no longer go to school, participate in sports, and today, it's over a year now, she's been seizure-free, and she's in college, and life's moving on. Her quality of life had been greatly impacted in a positive way. And that's kind of what we're seeing in most of our patients. Now, we only have a couple of patients who have gotten to a year post-therapy, but many more are in the queue. And I would say, from what we've said publicly, the majority of our patients are either completely seizure-free after the procedure, or they've shown a great reduction in the number of seizures they're having, as well as the severity of the seizures. MobiHealthNews: How about Parkinson's patients? You mentioned that was one use case. Rosa: So, that's an area that's under development now, and what they do with those patients, it's different for every one of these indications, but in Parkinson's patients, really the physiological issue for those patients is that they all show a reduction in dopamine production in the brain, and there is a direct relationship between dopamine and people that have Parkinson's. They all have dopamine deficiencies, and for some reason, when you stimulate brain tissue, it increases dopamine production, which then is able to reduce or completely control the amount of movement disorders or episodes that these patients have. But it's purely, it's a device that really the main function is to stimulate the brain tissue, and that's still in development for us. MobiHealthNews: How invasive is the surgery to do the implants? Rosa: So, you know, invasive is, it's actually a relative word. So, our technology is less invasive than what a Neuralink would be, and it's a different type of invasive than what Precision Neurosciences does. So, the link for us with Zimmer is that Zimmer Biomet has this robot that is used to pre-drill the holes in the skull that allow for the electrodes to be inserted exactly in the precise areas of the brain that the doctor may want. If you look at one of our devices, it's actually 0.8 millimeters in diameter, so it is a little bit thicker than a wire, and what this robot does is it pre-drills the holes wherever the doctor wants the device to go. There's no skull that's removed. There's nothing like that. It's just a tiny hole. And if you would have this type of surgery, let's just say today, and you were discharged tomorrow, in a lot of these cases, they don't even shave the skull on the patient. So no one would know that you had brain surgery. So, it's still what I would consider invasive, but not as invasive, whereas they have to remove bone and things like that to place the devices. One of the areas that we're going after is lower-back pain. The way they treat patients that have lower-back pain is they put these wire electrodes in through a needle that's placed in the back, and what we can do is take one of our film devices, and instead of the doctor having to make an incision in the back, you can literally thread that through the same needle, but the beauty of it is, is that now you can stimulate a much broader area in the back without the patient ever having to get an incision for that. So, in the brain, it requires a small hole, but in other parts of the body, we really designed the other technologies to be able to just fit right through a needle that these doctors are accustomed to using.

2026 年开年，二级市场的投资主线完成重磅切换，脑机接口赛道以燎原之势取代创新药，成为资本竞相追捧的核心风口，而这波热潮的核心推手，正是被市场称作 “马年核心标的” 的马斯克。 从新能源到商业航天，马斯克每一次赛道突破都带动 A 股相关板块掀起波澜，新年伊始旗下 Neuralink 脑机接口量产的官宣，更是让国内资本彻底 “唯马斯克马首是瞻”。 此次 Neuralink 的技术突破，真正击中了侵入式脑机接口的行业痛点：传统植入手术耗时数小时、临床风险高，而升级后的 R2 机器人实现颠覆性突破，将单电极插入速度从 17 秒大幅缩短至 1.5 秒，整体手术时间降至几分钟，电极可直接穿过硬脑膜无需移除，既从根本上解决了电极线退缩、术后感染的早期核心痛点，让原本高门槛的植入手术走向常规化，为脑机接口大规模商业化铺平了道路。 然而，在资本市场的狂热背后，却藏着不容忽视的现实：Neuralink 量产的消息固然劲爆，A 股市场中却鲜有真正深耕、落地脑机接口核心技术的标的，多数标的并无实质布局与技术积累。但这丝毫没有阻挡投资者的狂热，资金蜂拥而入推高相关概念股。火爆的脑机接口概念背后，难道真的只是国内投资者的南柯一梦？ 01 何为脑机接口？ 把握脑机接口的投资逻辑，必先明晰其技术内核与发展现状。 脑机接口是在大脑与外部设备之间建立的直接信息连接通路，大脑思维活动产生的脑电波，通过脑机接口完成特征识别、意图读取，最终转化为计算机指令，实现人与机器、外部环境的高效交互，是融合神经工程、人工智能、微电子、材料科学等多领域的交叉前沿技术。 按照技术路线划分，共可分为侵入式、非侵入式、半侵入式三大类，形成了截然不同的应用场景、技术壁垒与发展节奏。 图：三大脑机接口技术路线，来源：西南证券 （1）侵入式：高信号质量伴高风险 侵入式脑机接口需通过外科手术将电极直接植入大脑皮层，能获取空间分辨率优、信噪比高的神经信号，是现阶段实现高精度脑机交互的核心路径，主要应用于阿尔茨海默病、帕金森病、重度肢体瘫痪等严肃医疗领域——这类疾病现有治疗方案难以逆转病情进程，侵入式脑机接口成为患者实现功能恢复的重要突破方向。 其核心短板在于临床风险高、研发与应用成本居高不下：植入电极易对大脑造成不可逆损伤，还可能引发免疫反应与愈合反应，导致采集信号逐步衰退甚至消失，形成“损伤-信号变差-更易损伤”的恶性循环。 （2）非侵入式：低风险易操作 非侵入式脑机接口通过直接贴附在头皮上的电极采集神经信号，无需损伤机体，具备操作简单、成本低廉、无侵入性创伤的核心优势，且不会引发免疫反应，临床风险大幅降低，成为推动脑机接口大众化、普及化的核心路径。其应用场景已突破轻度神经功能障碍康复治疗，向失眠、焦虑症、偏头痛等消费医疗领域延伸，市场空间持续拓宽。 （3）半侵入式：权衡利弊的折中方案 半侵入式脑机接口兼顾信号质量与创伤风险，信号采集效果优于非侵入式，临床风险远低于侵入式，是未来医疗应用领域最具潜力的“折中方案”。目前行业探索方向持续创新，新增微创血管支架电极阵列、入耳式电子器件、硬膜外微创植入等技术路径，进一步平衡安全性与信号精度。 该路径与侵入式技术在工作流程、系统架构、核心组件类别上高度相似，但因植入位置（大脑表面、静脉血管等浅层部位）的差异，组件形态、技术要求与挑战存在显著不同。 02 全球发展风向标 从全球视角看，脑机接口的技术发展呈现出清晰的阶段目标：短期看生物相容性与信号稳定性的突破，中期看完全无线化与微创化的实现，长期则以双向闭环交互为终极形态。 这一系列技术难点的攻克，不仅依赖全球学术领域的持续创新，更吸引了众多优质企业投入研发，其中美国企业在核心环节占据前沿优势，既有整机系统龙头，也有上游核心部件服务商，形成了完整的技术探索矩阵。 美国的脑机接口企业主要聚焦于侵入式与半侵入式高端赛道，在膜材料、电极开发、算法迭代等核心环节具备显著的前沿创新性，Neuralink、Synchron、Precision Neuroscience 成为三大代表性企业，各自走出了差异化的技术发展路径。 （1）Neuralink：侵入式标杆 成立于 2016 年的 Neuralink，是全球侵入式脑机接口的绝对明星，自成立以来累计融资超 10 亿美元，其中包括 2025 年完成的 6.5 亿美元 E 轮融资，尽管尚未登陆二级市场，却早已成为全球投资市场的焦点。 这一路线技术难点集中在侵入式植入的生物相容性、信号稳定性和手术效率三大维度。Neuralink通过持续优化电极材料、升级高敏感度神经信号处理算法，有效补偿信号衰减。2025 年更是完成电极设计升级，使其能更深插入大脑皮层，兼容 99% 的人体解剖变异。 图：N1植入体的工作原理，来源：国金证券 同时，针对海量神经元数据（约 200Mbps）传输的带宽问题，Neuralink 开发了专有数据压缩算法，目标实现 200 倍无损压缩，并在 2024 年通过全球压缩挑战广泛征求外部解决方案。随着带宽问题的逐步解决，Neuralink 计划未来将电极数量扩展到数千个，实现更高分辨率的脑机交互。而 R2 手术机器人的引入，更是从根本上解决了手术安全性痛点，大幅降低人为操作错误，推动侵入式脑机接口向临床常规化应用迈进。 （2）Synchron：血管介入创新路径 不同于Neuralink的科技属性，Synchron 更偏向高值耗材医疗器械企业，其核心产品 Stentrode 是一款创新的血管内植入式脑机接口设备，通过微创手术部署于大脑静脉中，彻底避免了传统的开颅手术，安全性上具备显著优势。保证高安全性的同时，Stentrode 的信号采集质量媲美传统亚硬膜电极阵列，能稳定记录宽带神经活动，包括与运动意图相关的核心信号，让患者可通过思维直接控制数字设备，实现点击、滚动、缩放等基础操作。 图：核心产品Stentrode示意图，来源：开源证券 在生物相容性方面，该设备采用支架电极特殊设计，能快速与血管壁内皮化整合，大幅减少炎症反应和血栓风险，临床数据显示，设备植入后无重大血管并发症，始终保持静脉通畅性；同时作为全内化系统，其避免了皮肤穿刺带来的感染隐患，进一步提升整体生物安全性。 在长期稳定性上，Stentrode 展现出优异的耐久性，一年期临床研究表明，其信号强度和质量保持稳定无显著衰减，设备无迁移或失效问题，适合慢性植入，为严重瘫痪患者实现长期功能独立性提供了可能。 （3）Precision Neuroscience：薄膜电极技术突破 Precision Neuroscience 是专注于脑机接口技术开发的创新企业，其核心产品 Layer 7 Cortical Interface 是一款薄膜微电极阵列，专为贴合大脑皮层表面设计，无组织损伤风险，通过专利的最小侵入性插入方法，可在大脑表面任意位置放置数千个信号采集通道，实现高分辨率的神经信号记录与刺激。无需开颅手术或刺穿大脑，在临床试点中已成功放置 4096 个电极，实现高带宽脑信号采集，在短期手术环境中可提供实时的高质量功能和结构信息。 生物相容性方面，Layer 7 采用柔性薄膜设计，仅邮票大小、厚度小于人类头发，可实现完全植入，包括表面电极和位于头骨与头皮之间的处理单元，确保安全可移除且不损伤健康脑组织，已在多项临床研究中证明其低感染风险和无严重不良事件。公司计划将该产品应用于帮助瘫痪或肌萎缩侧索硬化（ALS）患者恢复运动或言语功能。 除了上述三家核心企业外，美国上游核心部件和技术服务商也迎来重要发展机遇，ClearPoint Neuro 提供的神经外科手术导航系统，是多家脑机接口企业植入手术的核心 “合作伙伴”，业务规模随手术量增长同步提升；NeuroOne 的薄膜电极技术已获 FDA 批准，应用于癫痫监测等临床场景，更早实现了稳定营收，成为行业发展的重要支撑。 03 国内企业的对标 中国脑机接口市场同样迎来发展热潮，但行业内企业呈现出显著的分化特征：既有埋头攻坚核心技术、推进临床落地的 “实干家”，也不乏借概念炒作、缺乏实际布局的 “跟风者”。 尽管麦澜德、美好医疗、翔宇医疗、乐普医疗等上市公司积极布局，但中国脑机接口的核心标的实则还是在一级市场中，脑虎科技、阶梯医疗、博睿康、强脑科技堪称其中的佼佼者。 （1）脑虎科技：对标 Neuralink 作为国内最接近 Neuralink 路线的企业，脑虎科技专注高通量柔性脑机接口研发，以 “全植入、全无线、全兼容” 为核心发展目标，是国内侵入式脑机接口赛道的核心探索者。 截至目前，脑虎科技已开展超过 50 例临床试验，成功实现患者通过意念操控轮椅、机械手等设备，其核心 “三全” 产品已进入临床验证阶段，技术路径直接对标国际前沿，临床推进速度位居国内前列，成为国内高端脑机接口赛道的重要希望。 （2）阶梯医疗：对标 Precision Neuroscience 阶梯医疗聚焦超柔性神经电极技术研发，核心优势在于高生物相容性与长期信号稳定性，与 Precision Neuroscience 的薄膜电极技术形成精准对标。 公司核心产品已进入 NMPA 创新医疗器械特别审查程序，完成多例前瞻性临床试验，成功实现患者脑控游戏、机械臂操作等功能，在柔性电极这一脑机接口核心材料领域形成了较高的技术壁垒，获得了监管层面的优先关注与政策支持。 （3）博睿康：对标 Synchron 博睿康采用硬膜外微创植入技术，通过硬币大小的微型装置实现脑机接口信号连接，既保证了信号采集质量，又大幅降低了临床手术风险，与 Synchron 的血管介入路径形成对标，是国内半侵入式赛道的核心代表。 核心产品已启动全国多中心注册临床试验，完成数十例设备植入，神经信号解码准确率处于行业高位，而微创化的技术路径更符合中国临床诊疗的接受度与应用场景，商业化落地速度有望领先行业，目前已进入创新医疗器械绿色通道。 （4）强脑科技：非侵入式龙头 强脑科技深耕非侵入式脑机接口赛道，与美国头部企业形成差异化的技术路径布局，其智能仿生手、脑电安睡仪等核心产品已成功走向消费医疗和康复市场，商业化能力在国内企业中尤为突出。 近期，强脑科技完成 20 亿元人民币重磅融资，并正式提交港股 IPO 申请，更是印证了资本对其商业化路径与市场布局的高度认可。 不过需要注意的是，非侵入式脑机接口的技术门槛与侵入式存在本质不同，其更多聚焦于消费医疗、轻康复及教育专注力训练等场景，与全球前沿的严肃医疗赛道形成互补，共同推动脑机接口的多元化发展。 04 概念股暴涨的真相 基于前述对脑机接口技术路径、全球企业布局的分析，投资者已能清晰把握当前赛道的整体境况。 令人深思的是，国内真正深耕脑机接口核心技术的标的多集中于一级市场，为何二级市场投资者依旧陷入疯狂追捧？这背后除了短期投机炒作的情绪推动，更暗藏着一重深层逻辑——一级市场与二级市场的双向对标联动。 对于尚处早期、盈利模式尚未清晰的一级市场脑机接口标的而言，“估值对标”是其发展过程中的关键逻辑支撑。无论是未来冲刺上市、释放估值预期，还是持续推进研发所需的后续融资，都需要二级市场存在可直接对标的上市公司，为其估值定价提供参照锚点。 在此逻辑下，二级市场标的的核心价值并非完全取决于自身技术实力与落地进展，更多是承担了一级市场标的“估值代言人”的角色。投资者对二级市场概念股的追捧，本质上是为一级市场脑机接口公司搭建估值对标体系，即便部分标的仅为概念沾边，也不妨碍其成为资本追捧的对象。 这也正是二级市场上演“集体狂欢后理性分化”经典戏码的核心原因。开年以来，美好医疗、三博脑科、翔宇医疗、南京熊猫等概念股频频登上龙虎榜，涨停板成为常态，投机资金的疯狂涌入推动板块短期涨幅飙升，成为A股开年最亮眼的风景线。而进入开年第二周，板块迎来分化调整，这其实正是资金投票形成最终龙头的过程。 二级市场的这场狂欢，也为一级市场核心标的注入了强劲动力。非侵入式龙头强脑科技实现20亿元里程碑式融资，正是资本对赛道信心的直接体现。但这仅仅是脑机接口时代的开端，随着马斯克旗下Neuralink后续量产进展、技术突破等热点持续释放，全球赛道热度将进一步攀升，国内一级市场也将涌现更多脑机接口企业的融资需求，大概率将推动脑机接口概念在2026年持续火热，成为贯穿全年的核心赛道。 从全球格局看，中国企业与美国龙头的技术路径对标；从资本维度看，一级市场与二级市场的估值体系对标。这双重对标相互交织、相互驱动，共同构成了当前脑机接口赛道的真实生态，也决定了赛道将在概念炒作与价值回归的博弈中，逐步迈向技术落地与商业化成熟的新阶段。 （来源：医曜 作者：陶秋骋） 药闻康策 新媒体矩阵微信公众号 点击下方  一键关注 【免责声明】 1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。 欢迎转发分享、点赞、点在看

FDA Clearance Further Validates Technology Platform and Offers Alternatives to Pharmaceutical and Invasive Surgical Treatments EDEN PRAIRIE, Minn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has received U.S. Food and Drug Administration (“FDA”) clearance to market its OneRF® Trigeminal Nerve Ablation System for use in procedures to create radiofrequency lesions for the treatment of pain, or for lesioning nerve tissue for functional neurosurgical procedures. As previously announced, the company completed the FDA submission earlier than anticipated and now targets a limited commercial launch in the fourth quarter of calendar 2025. This clearance leverages the Company’s proprietary OneRF® Ablation System RF generator platform for the treatment of trigeminal neuralgia, a chronic pain condition affecting approximately 150,000 people in the United States annually1. The trigeminal nerve is the main sensory nerve in the face associated with triggering excruciating pain for this condition. Trigeminal neuralgia is typically treated with medication or invasive procedures, including microvascular decompression (MVD), radiosurgery, or other percutaneous techniques. The OneRF® Trigeminal Nerve Ablation System features a minimally invasive surgical technology to treat severe, chronic facial pain. The system delivers targeted radiofrequency (RF) energy to ablate trigeminal nerve fibers, interrupting pain signaling. Differentiated features of this system include a “first-of-its-kind” multi-contact RF probe that allows for both precise localization and tailored ablation of the pain-conducting nerve tissue – using the same RF probe, and under temperature-controlled conditions which enhance safety and accuracy. This system may allow for reduced procedural time, improved patient comfort and improved patient safety. “One of the key aspects of the OneRF® technology platform is its potential to be effective across multiple neurological disorders and pain management functions,” said Dave Rosa, Chief Executive Officer of NeuroOne. “This is our first venture in pain management therapies and this newest technology aligns well with current commercial efforts with our OneRF® brain ablation system. Some of the current users for the OneRF® brain ablation system also perform nerve ablation procedures for facial pain, which may allow current medical practices to further justify the investment. Furthermore, we expect to pursue additional opportunities leveraging our technology platform in pain management and other therapeutic applications, such as treatment of lower back pain. With this clearance, we will continue our ongoing discussions with strategic partners and have the potential to begin generating revenues from trigeminal nerve ablation as soon as late calendar year 2025.” About NeuroOne NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, monitoring, ablation, drug delivery and stimulation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com. Forward Looking Statements This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “forecasts,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the timing and success of our commercial launch of the OneRF® Trigeminal Nerve Ablation System, our ability to obtain revenues from such launch in calendar 2025, the ability for our product to allow for reduced procedural time, improved patient comfort and improved patient safety, our ability to leverage our platform to pursue additional opportunities in pain management and other therapeutic applications, and our business strategy, market size, and other potential growth opportunities. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations for the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future. Caution: Federal law restricts this device to sale by or on the order of a physician. IR Contact MZ Group – MZ North AmericaNMTC@mzgroup.us 1 American Association of Neurological Surgeons (AANS) - April 2024